celecoxib has been researched along with Peptic Ulcer in 60 studies
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was no significant difference in the overall incidence of gastroduodenal ulcers at 12-week endpoint for celecoxib compared to diclofenac (2." | 9.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 9.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 9.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| "In this study, all dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen." | 9.09 | Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. ( Geis, GS; Graham, DY; Hubbard, RC; Isakson, PC; Kivitz, AJ; Lipsky, PE; Simon, LS; Verburg, KM; Weaver, AL; Yu, SS; Zhao, WW, 1999) |
| "Gastroduodenal ulcer rates after celecoxib and naproxen treatment were 4% versus 19% in the 0-4 wk interval (p < 0." | 9.09 | Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. ( Burr, AM; Correa, P; Geis, GS; Goldstein, JL; Hubbard, RC; Verburg, KM; Zhao, WW, 2001) |
| "Although nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed globally, their chronic use increases the risk of upper gastrointestinal (GI) damage." | 6.78 | Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. ( Kawai, T; Nakamura, S; Sakamoto, C; Sugioka, T; Tabira, J, 2013) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "There was no significant difference in the overall incidence of gastroduodenal ulcers at 12-week endpoint for celecoxib compared to diclofenac (2." | 5.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 5.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 5.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| " In addition, more patients receiving celecoxib developed dyspepsia than patients receiving lansoprazole and naproxen." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "In this study, all dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen." | 5.09 | Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. ( Geis, GS; Graham, DY; Hubbard, RC; Isakson, PC; Kivitz, AJ; Lipsky, PE; Simon, LS; Verburg, KM; Weaver, AL; Yu, SS; Zhao, WW, 1999) |
| "Gastroduodenal ulcer rates after celecoxib and naproxen treatment were 4% versus 19% in the 0-4 wk interval (p < 0." | 5.09 | Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. ( Burr, AM; Correa, P; Geis, GS; Goldstein, JL; Hubbard, RC; Verburg, KM; Zhao, WW, 2001) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "Although nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed globally, their chronic use increases the risk of upper gastrointestinal (GI) damage." | 2.78 | Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. ( Kawai, T; Nakamura, S; Sakamoto, C; Sugioka, T; Tabira, J, 2013) |
| "Celecoxib was predefined to be noninferior to placebo if the upper limit of the 95% CI for the hazard ratio (HR) with celecoxib was <1." | 2.77 | The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. ( Arber, N; Bertagnolli, MM; Coindreau, J; Eagle, C; Hawk, ET; Lanas, A; Levin, B; Lieberman, D; Sands, GH; Wang, TC; Zauber, A; Zhang, R, 2012) |
| "Many individuals with gastroduodenal ulcers require on-going, non-steroidal anti-inflammatory drug (NSAID) or anti-platelet therapy." | 2.74 | A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing. ( Aisenberg, J; Bamji, N; Bodian, C; Brooks, A; Cohen, L; Desai, J; Dikman, A; Miller, K; Sanyal, S; VON Althann, C; Whitson, M, 2009) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Celecoxib and rofecoxib have been used in Norway since 2000." | 2.41 | [A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002) |
| "All the patients aged ≥ 20 years with a diagnosis of cirrhosis hospitalized for variceal bleeding and non-variceal upper GI adverse events (oesophageal, gastric, duodenal ulcer, bleeding; gastritis and duodenitis) in 2006 were identified using ICD-9-CM diagnosis codes from inpatient claims from the Taiwan National Health Insurance Database." | 1.38 | Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. ( Chang, CH; Chen, HC; Lai, MS; Lee, YC; Lin, JW; Lin, MS, 2012) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "Endoscopy was performed to document any gastroduodenal ulcers with or without ulcer complications." | 1.36 | Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. ( Chang, FY; Chen, TS; Hsiang, KW; Lee, KC; Lee, SD; Lin, HC; Lin, HY; Lu, CL; Luo, JC, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.67) | 18.2507 |
| 2000's | 47 (78.33) | 29.6817 |
| 2010's | 9 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almansa, C | 1 |
| Alfón, J | 1 |
| de Arriba, AF | 1 |
| Cavalcanti, FL | 1 |
| Escamilla, I | 1 |
| Gómez, LA | 1 |
| Miralles, A | 1 |
| Soliva, R | 1 |
| Bartrolí, J | 1 |
| Carceller, E | 1 |
| Merlos, M | 1 |
| García-Rafanell, J | 1 |
| Liu, D | 1 |
| Guo, M | 1 |
| Hu, Y | 1 |
| Liu, T | 1 |
| Yan, J | 1 |
| Luo, Y | 1 |
| Yun, M | 1 |
| Yang, M | 1 |
| Zhang, J | 1 |
| Guo, L | 1 |
| Feng, GS | 1 |
| Ma, JL | 1 |
| Wong, BC | 2 |
| Zhang, L | 1 |
| Liu, WD | 1 |
| Pan, KF | 1 |
| Shen, L | 1 |
| Zhang, XD | 1 |
| Li, J | 1 |
| Xia, HH | 1 |
| Li, JY | 1 |
| Lam, SK | 2 |
| You, WC | 1 |
| Patterson, MK | 1 |
| Castellsague, J | 2 |
| Walker, AM | 1 |
| Dikman, A | 1 |
| Sanyal, S | 1 |
| VON Althann, C | 1 |
| Whitson, M | 1 |
| Desai, J | 1 |
| Bodian, C | 1 |
| Brooks, A | 1 |
| Bamji, N | 1 |
| Cohen, L | 1 |
| Miller, K | 1 |
| Aisenberg, J | 1 |
| Cheung, R | 1 |
| Cheng, TT | 1 |
| Dong, Y | 1 |
| Lin, HY | 2 |
| Lai, K | 1 |
| Lau, CS | 1 |
| Feng, H | 1 |
| Parsons, B | 1 |
| Chan, FK | 3 |
| Lanas, A | 2 |
| Scheiman, J | 1 |
| Berger, MF | 1 |
| Nguyen, H | 1 |
| Goldstein, JL | 6 |
| Hsiang, KW | 1 |
| Chen, TS | 1 |
| Luo, JC | 1 |
| Lu, CL | 1 |
| Lin, HC | 1 |
| Lee, KC | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Wallace, JL | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Niebling, W | 1 |
| Lee, YC | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Chen, HC | 1 |
| Lin, MS | 1 |
| Lai, MS | 1 |
| Arber, N | 1 |
| Lieberman, D | 1 |
| Wang, TC | 1 |
| Zhang, R | 1 |
| Sands, GH | 1 |
| Bertagnolli, MM | 1 |
| Hawk, ET | 1 |
| Eagle, C | 1 |
| Coindreau, J | 1 |
| Zauber, A | 1 |
| Levin, B | 1 |
| Sakamoto, C | 2 |
| Kawai, T | 1 |
| Nakamura, S | 1 |
| Sugioka, T | 1 |
| Tabira, J | 1 |
| McCormack, JP | 1 |
| Rangno, R | 1 |
| Geis, GS | 5 |
| Stover, RR | 1 |
| Slørdal, L | 1 |
| Wibe, E | 1 |
| Maehlum, S | 1 |
| Graham, DY | 2 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Sturkenboom, MC | 1 |
| Burke, TA | 1 |
| Dieleman, JP | 1 |
| Tangelder, MJ | 1 |
| Lee, F | 1 |
| Lamarque, D | 1 |
| Hawkey, CC | 1 |
| Svoboda, P | 1 |
| Fiedorowicz-Fabrycy, IF | 1 |
| Nasonov, EL | 1 |
| Pikhlak, EG | 1 |
| Cousin, M | 1 |
| Gitton, X | 1 |
| Hoexter, G | 1 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Wu, JC | 1 |
| Leung, WK | 1 |
| Lee, YT | 1 |
| To, KF | 1 |
| Chung, SC | 1 |
| Sung, JJ | 1 |
| Cryer, B | 1 |
| Klasser, GD | 1 |
| Epstein, J | 1 |
| Lai, KC | 1 |
| Chu, KM | 1 |
| Hui, WM | 1 |
| Hu, WH | 1 |
| Wong, WM | 1 |
| Chan, AO | 1 |
| Wong, J | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Perez-Gutthann, S | 1 |
| Pilotto, A | 1 |
| Seripa, D | 1 |
| Franceschi, M | 1 |
| Scarcelli, C | 1 |
| Colaizzo, D | 1 |
| Grandone, E | 1 |
| Niro, V | 1 |
| Andriulli, A | 1 |
| Leandro, G | 1 |
| Di Mario, F | 1 |
| Dallapiccola, B | 1 |
| Hiratsuka, T | 1 |
| Peura, D | 1 |
| Wilcox, CM | 1 |
| Niculescu, L | 1 |
| Berger, M | 1 |
| Fidler, MJ | 1 |
| Argiris, A | 1 |
| Patel, JD | 1 |
| Johnson, DH | 1 |
| Sandler, A | 1 |
| Villaflor, VM | 1 |
| Coon, J | 1 |
| Buckingham, L | 1 |
| Kaiser, K | 1 |
| Basu, S | 1 |
| Bonomi, P | 1 |
| Schachna, L | 1 |
| Ryan, PF | 1 |
| Simon, LS | 2 |
| Weaver, AL | 1 |
| Kivitz, AJ | 1 |
| Lipsky, PE | 1 |
| Hubbard, RC | 3 |
| Isakson, PC | 1 |
| Verburg, KM | 4 |
| Yu, SS | 1 |
| Zhao, WW | 3 |
| Dionne, R | 1 |
| Megeff, CE | 1 |
| Strayer, SM | 1 |
| Blondon, H | 1 |
| Silverstein, FE | 2 |
| Agrawal, NM | 2 |
| Kaiser, J | 1 |
| Maurath, CJ | 1 |
| Faich, G | 1 |
| Pincus, T | 1 |
| Whelton, A | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Stenson, WF | 1 |
| Burr, AM | 2 |
| Kent, JD | 1 |
| Lefkowith, JB | 1 |
| Tive, L | 1 |
| Correa, P | 1 |
| Bates, DE | 1 |
| Lemaire, JB | 1 |
| Lems, WF | 1 |
| van de Laar, MA | 1 |
| Bijlsma, JW | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Nguyen, A | 1 |
| Chaiton, A | 1 |
| Hawkey, CJ | 1 |
| Nakamura, H | 1 |
| Hrachovec, JB | 1 |
| Mora, M | 1 |
| Wright, JM | 1 |
| Perry, TL | 1 |
| Bassett, KL | 1 |
| Chambers, GK | 1 |
| Brinker, AD | 1 |
| Bonnel, RA | 1 |
| Feight, AG | 1 |
| Nourjah, P | 1 |
| Pomp, E | 1 |
| Tsuji, S | 1 |
| Kawano, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102] | Phase 4 | 4,484 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects[NCT00994461] | Phase 4 | 190 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 0.058 |
| Oral Diclofenac Plus Omeprazole | 0.073 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | ug/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -3.396 |
| Oral Diclofenac Plus Omeprazole | -1.990 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.306 |
| Oral Diclofenac Plus Omeprazole | -1.425 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | grams (g)/deciliter (dL) (Least Squares Mean) |
|---|---|
| Celecoxib | -0.017 |
| Oral Diclofenac Plus Omeprazole | -0.423 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | microgram (ug)/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 2.517 |
| Oral Diclofenac Plus Omeprazole | 1.952 |
"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 0.754 |
| Oral Diclofenac Plus Omeprazole | 0.773 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 2018 |
| Oral Diclofenac Plus Omeprazole | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 82 |
| Oral Diclofenac Plus Omeprazole | 79 |
A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 45 |
| Oral Diclofenac Plus Omeprazole | 123 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 20 |
| Oral Diclofenac Plus Omeprazole | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 25 |
| Oral Diclofenac Plus Omeprazole | 92 |
"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 132 |
| Oral Diclofenac Plus Omeprazole | 162 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 5 |
| Oral Diclofenac Plus Omeprazole | 11 |
"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 114 |
| Oral Diclofenac Plus Omeprazole | 167 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | IU/L (Least Squares Mean) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | -2.689 | -0.901 | -1.151 |
| Oral Diclofenac Plus Omeprazole | 7.455 | 1.490 | 5.213 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | |
|---|---|---|
| History of GD Ulceration (n=395, 400) | No History of GD Ulceration (n=1843, 1846) | |
| Celecoxib | 7 | 13 |
| Oral Diclofenac Plus Omeprazole | 13 | 68 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | 26 | 8 | 13 |
| Oral Diclofenac Plus Omeprazole | 86 | 12 | 27 |
The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) |
|---|---|
| Celecoxib | 1.4 |
| Loxoprofen | 27.6 |
| Placebo | 2.7 |
The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) |
|---|---|
| Celecoxib | 24.3 |
| Loxoprofen | 47.4 |
| Placebo | 16.2 |
The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) | |
|---|---|---|
| Gastric ulcers | Duodenal ulcers | |
| Celecoxib | 0 | 1.4 |
| Loxoprofen | 25.0 | 5.3 |
| Placebo | 2.7 | 0 |
The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) | ||
|---|---|---|---|
| Gastroduodenal ulcers and/or erosions | Gastric ulcers and/or erosions | Duodenal ulcers and/or erosions | |
| Celecoxib | 36.5 | 35.1 | 4.1 |
| Loxoprofen | 53.9 | 53.9 | 5.3 |
| Placebo | 24.3 | 24.3 | 0 |
Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 erosion | 1 erosion | 2 erosions | 3 erosions | 4 erosions | 5 erosions | 6 erosions | 7 erosions | 8 erosions | 9 erosions | 10 or more erosions | |
| Celecoxib | 47 | 14 | 4 | 5 | 0 | 0 | 2 | 1 | 0 | 0 | 1 |
| Loxoprofen | 41 | 13 | 3 | 9 | 4 | 3 | 1 | 1 | 1 | 0 | 0 |
| Placebo | 29 | 5 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 ulcer | 1 ulcer | 2 ulcers | 3 ulcers | 4 ulcers | 5 ulcers | 6 ulcers | 7 ulcers | 8 ulcers | 9 ulcers | 10 or more ulcers | |
| Celecoxib | 73 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Loxoprofen | 55 | 10 | 5 | 2 | 0 | 0 | 1 | 2 | 1 | 0 | 0 |
| Placebo | 36 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Score 0 | Score 1 | Score 2 | Score 3 | Score 4 | Score 5 | Score 6 | Score 7 | |
| Celecoxib | 38 | 8 | 1 | 22 | 4 | 0 | 0 | 1 |
| Loxoprofen | 33 | 2 | 0 | 19 | 1 | 0 | 0 | 21 |
| Placebo | 22 | 6 | 0 | 8 | 0 | 0 | 0 | 1 |
15 reviews available for celecoxib and Peptic Ulcer
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
[The choice of selective COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Peptic Ulce | 2007 |
[The choice of selective COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Peptic Ulce | 2007 |
COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Hum | 2000 |
Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Hum | 2000 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Inci | 2001 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Inci | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pep | 2001 |
Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pep | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Arthritis. Should you be taking a COX-2 inhibitor?
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo | 2001 |
Arthritis. Should you be taking a COX-2 inhibitor?
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo | 2001 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Neutrophil-endothelium interaction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Adhesion; Cell Adhesion Molecules; | 2002 |
[Neutrophil-endothelium interaction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Adhesion; Cell Adhesion Molecules; | 2002 |
15 trials available for celecoxib and Peptic Ulcer
| Article | Year |
|---|---|
Effect of sanhuangwuji powder, anti-rheumatic drugs, and ginger-partitioned acupoint stimulation on the treatment of rheumatoid arthritis with peptic ulcer: a randomized controlled study.
Topics: Acupuncture Points; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Drugs, Chinese Her | 2015 |
Effect of sanhuangwuji powder, anti-rheumatic drugs, and ginger-partitioned acupoint stimulation on the treatment of rheumatoid arthritis with peptic ulcer: a randomized controlled study.
Topics: Acupuncture Points; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Drugs, Chinese Her | 2015 |
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Topics: Adult; Cardiovascular Diseases; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Dose-Response Relatio | 2008 |
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Topics: Adult; Cardiovascular Diseases; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Dose-Response Relatio | 2008 |
A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clopidogrel; Drug Administ | 2009 |
A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clopidogrel; Drug Administ | 2009 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy | 2010 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cycloo | 2013 |
Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cycloo | 2013 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell L | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell L | 2008 |
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal | 1999 |
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal | 1999 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclo | 2001 |
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclo | 2001 |
30 other studies available for celecoxib and Peptic Ulcer
| Article | Year |
|---|---|
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites | 2003 |
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites | 2003 |
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2008 |
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2008 |
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; | 2010 |
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; | 2010 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
[Bringing evidence to practice: obstacles and barriers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comparative Effectiveness Research; Conflict of | 2011 |
[Bringing evidence to practice: obstacles and barriers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comparative Effectiveness Research; Conflict of | 2011 |
Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comorbidity; Cyc | 2012 |
Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comorbidity; Cyc | 2012 |
Digging for data from the COX-2 trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Random | 2002 |
Digging for data from the COX-2 trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Random | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenas | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenas | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cycloox | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cycloox | 2002 |
[Celecoxib and the CLASS study--worse and worse...].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Celecoxib and the CLASS study--worse and worse...].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Celecoxib and the CLASS study--a statement].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Celecoxib and the CLASS study--a statement].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2003 |
[Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2003 |
Underutilization of preventive strategies in patients receiving NSAIDs.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cohort | 2003 |
Underutilization of preventive strategies in patients receiving NSAIDs.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cohort | 2003 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
[Capsule endoscopy study of gastrointestinal tolerance. Coxibes superior to NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cycl | 2004 |
[Capsule endoscopy study of gastrointestinal tolerance. Coxibes superior to NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cycl | 2004 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2004 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2004 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cas | 2007 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cas | 2007 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans | 2008 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans | 2008 |
New versus old drugs for arthritis.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Huma | 1999 |
New versus old drugs for arthritis.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Huma | 1999 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
COX-2 inhibitors: better than ibuprofen for dental pain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 1999 |
COX-2 inhibitors: better than ibuprofen for dental pain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 1999 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2000 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2000 |
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycl | 2000 |
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycl | 2000 |
Possible celecoxib-induced gastroduodenal ulceration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Male; Middle Aged; Peptic Ulcer; Pyrazol | 2001 |
Possible celecoxib-induced gastroduodenal ulceration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Male; Middle Aged; Peptic Ulcer; Pyrazol | 2001 |
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
Celecoxib and rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2001 |
Celecoxib and rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2001 |